clinical trial · NCT06049095
A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants
Latigo Biotherapeutics·phase1·active not recruiting·n = 204
HealthyLTG-001Placebo
brief summary
This is a sequential, randomized, double-blind, placebo-controlled Phase 1 single (SAD) and multiple (MAD) ascending dose study to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally or intravenously administered LTG-001 in healthy male and female participants
started
Oct 17, 2023
primary completion
Sep 1, 2026
completion
Sep 1, 2026
last updated
Jun 16, 2026
official title
A Sequential, Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally of Intravenously to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Male and Female Participants 18 to 55 Years of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol